Physician profile
Laura Ucik
NPI 1255863254
$793.38
in general payments reported to CMS, 2019-2025
14 companies · $183 in 2025
The $183 reported for 2025 was more than what a typical Family Medicine provider received nationally (typical 2025 total: $153).
Payments by year
General payments by program year, as reported to CMS.
General payments by year: 2021: $65.61 · 2022: $94.26 · 2023: $210 · 2024: $241 · 2025: $183.
What the payments were for
Nature of payment as categorized by the reporting companies: meals, consulting, travel, and so on.
Food and Beverage: $634.
View as a table
| Payment type | Amount (2023-2025) |
|---|---|
| Food and Beverage | $633.51 |
Payment-type detail covers 2023-2025; earlier years are included in totals but not broken out here.
Who reported paying
General payments only, as reported to CMS. Product names cover 2023-2025.
| Company | General payments | Years | Top products |
|---|---|---|---|
| Lilly USA, LLC | $146.75 | 2021-2025 | Mounjaro, Zepbound, Jardiance |
| Alkermes, INC. | $146.72 | 2023-2025 | Vivitrol, Vivitrol |
| Glaxosmithkline, LLC. | $121.53 | 2021-2025 | Trelegy Ellipta |
| Novo Nordisk INC | $87.21 | 2021-2025 | Wegovy, Rybelsus, Ozempic |
| Pfizer INC. | $48.43 | 2023-2025 | |
| Astrazeneca Pharmaceuticals LP | $47.41 | 2022-2025 | Breztri, Airsupra |
| Indivior INC. | $41.41 | 2023 | Sublocade |
| Exact Sciences Corporation | $35.92 | 2024-2025 | Cologuard Collection Kit, The Cologuard Plus Collection Kit |
| Dexcom, INC. | $32.95 | 2024 | Dexcom G6 Transmitter |
| Braeburn INC. | $20.61 | 2024 | Brixadi |
| Mylan Specialty L.P. | $17.90 | 2023 | Yupelri |
| Corcept Therapeutics | $16.96 | 2024 | Korlym |
| Amgen INC. | $15.21 | 2023 | Otezla, Repatha |
| Merck Sharp & Dohme LLC | $14.37 | 2025 | Capvaxive, Rotateq, Gardasil 9 |
Drugs and devices associated with these payments
CMS records which products a payment was associated with, not how the money was allocated. Association is not allocation: one payment can be associated with several products, and a product listing does not mean the payment was made because of that product. Product detail covers 2023-2025.
If you want to bring it up
Most clinicians are glad to talk about this. A respectful way in:
- "I saw Laura Ucik listed in the CMS Open Payments database. Can you tell me about your work with those companies?"
- "Is there a generic or alternative to this medication, and would it work as well for me?"
- "What made you choose this particular treatment for my situation?"
These are normal questions. A good clinician will welcome them.
Share this page
Keep an eye on this page
Get an email when the next June refresh changes this page. No account needed.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.